Dominika Szlichta

Dominika Szlichta

Auto-generated profile, based on publicly available information

Dominika Szlichta

Toxicology Clinic, Medical University, Lublin, Poland

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2022 in Annals of Agricultural and Environmental Medicine
Verified
Journal Article
Open access
AOAnna Orzeł
Anna Orzeł
WFWojciech Flieger
Wojciech Flieger
DSDominika Szlichta
Dominika Szlichta
BTBarbara Terpiłowska
Barbara Terpiłowska
MTMichał Terpiłowski
Michał Terpiłowski
JSJarosław Szponar
Jarosław Szponar
Introduction: Clinical manifestation of organophosphates toxicity may be differentiate and include cholinergic toxidrome, intermediate syndrome, OP-induced delayed polyneuropathy to chronic OP-induced neuropsychiatric disorder (OPIDN). Patients symptoms, along with decrease in cholinesterase...

14 June 2021 in Annals of Agricultural and Environmental Medicine
Verified
Journal Article
Open access
BKBarbara Zofia Klatka
Barbara Zofia Klatka
MTMichał Terpiłowski
Michał Terpiłowski
AOAnna Orzeł
Anna Orzeł
DJDominika Janeczko
Dominika Janeczko
MHMagdalena Hołowczuk
Magdalena Hołowczuk
JSJarosław Szponar
Jarosław Szponar
Introduction: Carbamate insecticides are methyl carbamic acid esters and reversible cholinesterase inhibitors. In contrast to the long-term action of organophosphate insecticides, this complex undergoes rapid hydrolysis. Case report: A suicidal poisoning by exposure to carbofuran in a...

1 June 2021 in Current Problems of Psychiatry
Verified
Journal Article
Open access
PDF file
MTMichał Terpiłowski
Michał Terpiłowski
BTBarbara Terpiłowska
Barbara Terpiłowska
AOAnna Orzeł
Anna Orzeł
DSDominika Szlichta
Dominika Szlichta
MŁMarcin Łata
Marcin Łata
MPMichał Próchnicki
Michał Próchnicki
Introduction: Susac syndrome (SuS) is a rare immune-mediated disease caused by occlusions of microvessels in the brain, retina and inner ear. It is characterized by the clinical triad of encephalopathy, visual disturbances and hearing loss. The diagnosis of SuS is based mainly on the clinical symptoms and the supporting tests in which characteristic changes occur in the MRI. Case report: Here, we present a case of a patient with possible SuS with psychiatric symptoms. A 31-year-old woman was admitted to the Department of Psychiatry due to deteriorating mental health for several weeks manifested as a negative mood and suicidal thoughts. During hospitalization, a neurological consultation was conducted, in which the patient was identified as conscious, psychomotor sluggish, with impaired verbal contact and persistent hearing and vision impairment. Cross-sectional assessment of cognitive functions revealed that the patient had a generalized syndrome of neuropsychological deficits, which confirms the diagnosis of dementia. Discussion: This case summary provides an example of a woman diagnosed with SuS manifested as a cognitive impairment with associated vision and hearing deterioration. It is worth emphasizing the fact that such presentation of the triad of at disease onset is rare. The characteristics of the organic changes in the brain described in the MRI probably explain the symptoms described in that case. The prognosis of SuS depends on early diagnosis and treatment. Conclusions: A diagnosis of SuS should always be considered in the presence of nonspecific neuropsychiatric symptoms and progressive multifocal neurological symptoms, hearing loss, and visual impairment. An important fact is that the typical triad of SuS symptoms in most cases does not occur simultaneously, which makes the diagnostic process very difficult and may lead to misdiagnosis.

14 July 2026 in Rheumatology
Verified
Journal Article
Open access
PDF file
DSDominika Szlichta
Dominika Szlichta
MDMagdalena Dryglewska
Magdalena Dryglewska
EŁEwa Łyś-Toporowska
Ewa Łyś-Toporowska
MMMaria Majdan
Maria Majdan
Introduction: Ankylosing spondylitis (AS) is a chronic inflammatory disease that can be managed with tumor necrosis factor (TNF) inhibitors. This study evaluated the effects of adalimumab, a TNF inhibitor, on inflammatory markers, including C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). Monitoring disease activity during therapy is important for assessing treatment response. Material and methods: We analyzed the medical history of 28 patients with confirmed AS, treated with adalimumab. The inflammatory markers neutrophil–lymphocyte ratio (NLR), platelet–lymphocyte ratio (PLR), monocyte–lymphocyte ratio (MLR), CRP, ESR, and the Bath Ankylosing Spondylitis Disease Activity Index were assessed at the beginning of the observation (month 0) and after 3, 6, and 12 months of therapy. Results: The mean NLR value after 3 months of treatment was 1.48 (95% confidence interval, CI: 0.92–2.03, p < 0.001), after 6 months was 1.48 (95% CI: 0.92–2.12, p < 0.001), and after 12 months was 1.67 (95% CI: 1.08–2.30, p < 0.001). Mean MLR value after 3 months of treatment was 0.07 (95% CI: 0.03–0.13, p = 0.005), after 6 months was 0.05 (95% CI: 0.00–0.11, p = 0.101), and after 12 months was 0.06 (95% CI: 0.01–0.11, p = 0.047), showing statistical significance only after 3 and 12 months. The mean PLR value after 3 months of treatment was 52.8 (95% CI: 30.1–79.60, p < 0.001), after 6 months was 65.50 (95% CI: 31.60–83.90, p < 0.001), and after 12 months was 68.80 (95% CI: 42.70–93.70, p < 0.001). Conclusions: Neutrophil–lymphocyte ratio may be a useful marker of inflammation in patients with AS. Monocyte–lymphocyte ratio and PLR require further investigation. Peripheral blood tests are simple and inexpensive to perform, making hematological markers promising tools for monitoring inflammatory diseases.